Biosimilar Naming: How Could the Suffix Impact the U.S. Health System?

Wednesday, February 27, 2019
Presented by: 
Eric Henry

Eric Henry, Clinical Content Specialist focused on the domestic drug file with Clinical Effectiveness at Wolters Kluwer, Heath, in a 45-minute live webinar to discuss: 

  • The potential impact of biosimilars at this tipping point in the pharmaceutical industry 
  • FDA-required suffixes and standards for biosimilars naming 
  • Prescription workflow best practices for small and large molecule biosimilars 
  • Issues raised by retrospective naming and products without suffixes 

The RxPerts Academy from Wolters Kluwer wants to help you better understand the impact of biosimilar naming conventions. Despite their potential to save the U.S. healthcare system billions of dollars, the widespread adoption of biosimilars has been slow, due to complexities in approving, naming, standardizing, and reporting on these new products.

You may also like:

Blog Post

The National Association of Chain Drug Stores (NACDS) Total Store Expo (TSE) is one of the year’s best attended events in the commercial healthcare industry, with a focus on categories thr...

View Blog Post
Blog Post

When drug therapy fails to achieve its objectives, it is frustrating for both the patients, whose health and well-being is on the line, and the providers, who believed they were recommending the best possible care. Pharmacogeno...

View Blog Post
Webinar

Discussion of the value and scope of USP <800> standards; the definition of hazardous drugs, the associated types of potential exposure, and where exposure may occur; importance of assessment of risk; and the responsibili...

View Webinar

Filter by Type

Sign up to receive the latest news and information!

Sign Up